Stay updated on Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial page.

Latest updates to the Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial page
- ChecktodayChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location, as well as the introduction of new drug names such as pembrolizumab and lenvatinib. The revision number has also been updated to v3.0.0.SummaryDifference3%
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.1%
- Check22 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check29 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference1%
- Check36 days agoChange DetectedThe web page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, and it now includes information about the HHS Vulnerability Disclosure.SummaryDifference0.2%
- Check43 days agoChange DetectedThe web page has been updated from version 2.16.5 to version 2.16.6.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial page.